The evidence-based pharmacological treatment of social anxiety disorder
The DOI matches its Crossref record.
Abstract
Social anxiety disorder (SAD) is a highly prevalent and often disabling disorder. This paper reviews the pharmacological treatment of SAD based on published placebo-controlled studies and published meta-analyses. It addresses three specific questions: What is the first-line treatment of SAD? How long should treatment last? What should be the management of treatment-resistant cases? Based on their efficacy for SAD and common comorbid disorders, tolerability, and safety, SSRIs should be considered as the first-line treatment for most patients. Less information is available regarding the optimal length of treatment, although individuals who discontinue treatment after 12-20 wk appear more likely to relapse than those who continue on medication. Even less empirical evidence is available to support strategies for treatment-resistant cases. Clinical experience suggests that SSRI non-responders may benefit from augmentation with benzodiazepines or gabapentin, or from switching to MAOIs, RIMAs, benzodiazepines or gabapentin. Cognitive-behavioural therapy may also be a helpful adjunct or alternative.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Experimental disclosure and its moderators: A meta-analysis.
Frattaroli, J. (2006) · Psychological Bulletin · doi:10.1037/0033-2909.132.6.823 · Cited by 1,502
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Treatment-resistant anxiety disorders
Bystritsky, A. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001852 · Cited by 289
Mörtberg, E., Clark, D. M., Sundin, Ö., & Åberg Wistedt, A. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00839.x · Cited by 213
“Within pharmacological approaches, the best validated treatments are: benzodiazepines, monoamine oxidase inhibitors and selective serotonin reuptake inhibitors (SSRI) (9) of which the welltolerated and safer drugs are the SSRIs, which are recommended as first-line treatments (10, 11).”
BackgroundBlanco, C., Heimberg, R. G., Schneier, F. R., Fresco, D. M., Chen, H., Turk, C. L., Vermes, D., Erwin, B. A., Schmidt, A. B., Juster, H. R., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.11 · Cited by 206
Self-citation
Metadata
- Authors
- Blanco, C., Raza, M. S., Schneier, F. R., & Liebowitz, M. R.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12
- Volume
- 6
- Issue
- 4
- Pages
- 427-442
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W1989650996
- Cited by
- 79
- References
- 0
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The evidence-based pharmacological treatment of social anxiety disorder. https://app.cochat.ai/papers/10.1017/s1461145703003791
- The paper
- Blanco, C., Raza, M. S., Schneier, F. R., & Liebowitz, M. R. (2003). The evidence-based pharmacological treatment of social anxiety disorder. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145703003791
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.